A Chinese patient with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin

At present, approximately 20% of Hodgkin lymphomas (HL) are relapsed and refractory, and therapeutic methods including chemotherapy, radiotherapy, and even stem cell transplantation are unsatisfactory. Brentuximab vedotin, composed of CD30 antibody and a chemotherapeutic agent, is a new targeted dru...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Zhi-Gang, Zhou, Hong-Wei, Peng, Chao-Jin, Liu, Mo, Du, Yu, Yang, Qing-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sun Yat-sen University Cancer Center 2013
Materias:
Case Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845561/
https://www.ncbi.nlm.nih.gov/pubmed/23544448
http://dx.doi.org/10.5732/cjc.012.10221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845561/
https://www.ncbi.nlm.nih.gov/pubmed/23544448
http://dx.doi.org/10.5732/cjc.012.10221

Ejemplares similares